Mark McDade

Managing Partner

Before joining Qiming in 2017, McDade was Executive Vice President, Chief Operating Officer at UCB. He led UCB’s worldwide Geographic Operations, Established Brands, Technical Operations and Business Development. He joined UCB’s Executive Committee in 2008.

From 2002 until late 2007, Mark served as Chief Executive Officer and a director of PDL Biopharma, an antibody-based biopharma located in Redwood City, CA, USA. Prior to PDL, he served as CEO of Signature Bioscience, located in San Francisco, CA. Mark was founder and a director of Corixa Corporation, where he served as Chief Operating Officer from September 1994 to December 1998 and as President and Chief Operating Officer from January 1999 until his departure in late 2000 to join Signature. Before Corixa, Mark was COO of Boehringer Mannheim Therapeutics, the bio-pharmaceutical division of Corange, and prior to that held several positions at Sandoz Ltd. Including business development, product management and general management.

Mark serves on the Board of directors of FivePrime Therapeutics (FPRX), Dermira (DERM) and Aimmune Therapeutics (AIMT), all publicly traded biotechs in the SF Bay Area. Mark received a B.A. from Dartmouth College and an M.B.A. from the Harvard Business School.